# OnCo record nct02152631 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct02152631/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct02152631", "NCT02152631" ;
  schema:name "A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer"@en ;
  schema:alternateName "JUNIPER"@en ;
  schema:description "A phase 3 trial of Abemaciclib, Erlotinib in non-small-cell lung cancer and small-cell lung cancer, run by Eli Lilly and Company, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct02152631/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02152631> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2014-10-03" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/sclc/> ;
  onco:technologies <https://onco.cc/technologies/cdk46-inhibitor/>, <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/abemaciclib/>, <https://onco.cc/drugs/erlotinib/> ;
  onco:companies <https://onco.cc/companies/eli-lilly/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-nct02152631-front-oncol-2020/> .